Found: 13
Select item for more details and to access through your institution.
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 3, p. 631, doi. 10.1007/s00432-020-03129-6
- By:
- Publication type:
- Article
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1357231
- By:
- Publication type:
- Article
Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.937924
- By:
- Publication type:
- Article
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 3, p. e395, doi. 10.1016/j.cllc.2020.06.005
- By:
- Publication type:
- Article
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1625, doi. 10.1007/s00262-021-03100-5
- By:
- Publication type:
- Article
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming.
- Published in:
- Advanced Therapeutics, 2023, v. 6, n. 11, p. 1, doi. 10.1002/adtp.202300141
- By:
- Publication type:
- Article
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 6, p. 1, doi. 10.1002/ctm2.1277
- By:
- Publication type:
- Article
Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.835225
- By:
- Publication type:
- Article
Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.652560
- By:
- Publication type:
- Article
Special issue "The advance of solid tumor research in China": Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 1, p. 15, doi. 10.1002/ijc.34123
- By:
- Publication type:
- Article
First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 5, p. 1043, doi. 10.1111/1759-7714.13025
- By:
- Publication type:
- Article
Atorvastatin suppressed proliferation and facilitated apoptosis of A549 cells through mediating recruitment of Fas and CD59 in lipid raft.
- Published in:
- Tropical Journal of Pharmaceutical Research, 2022, v. 21, n. 2, p. 237, doi. 10.4314/tjpr.v21i2.4
- By:
- Publication type:
- Article
Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1001503
- By:
- Publication type:
- Article